Citations

Clear

3053 citation(s) found for "Patel, A".

Invited Commentary: Mind the Gap: The Radiologist’s Role in Reporting Observations in the Postprocedure Uterus
Young, Scott W. , Patel, Maitray D , Young, Scott W , Patel, Maitray D.

Mayo Clinic

RadioGraphics | June 18, 2026 | Volume: 46 | Issue: 7 | Pages: No page available

10.1148/rg.250251 | PMID 42313624 Get It

Research through Evaluation for Large Language Model in Patient-Clinician Communications
Holmes, Jason, Hobson, Jared, Bennett, Alexandra, McKone, Elizabeth L. , Ebner, Daniel, Shiraishi, Satomi, Patel, Samir H. , Yu, Nathan Y. , Hallemeier, Chris L., Ball, Brooke E., Waddle, Mark, Liu, Wei, Hao, Yuexing , Holmes, Jason , Routman, David M. , Kalantari, Saleh , Ghassemi, Marzyeh

Mayo Clinic

No container title available | June 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9735115/v1 | PMID 42370275 Get It

Abstract Large Language Models (LLMs) demonstrate strong capabilities in healthcare applications. However, recruiting human evaluators to assess usability and effectiveness becomes challenging in the large-scale LLM-generated outcomes. Existing metrics are often outdated for evaluating LLM-based healthcare technologies. This paper proposes a Research through Evaluation (RtE) approach that can refine metrics and improve assessments of LLM-generated outputs. We deploy RtE in a retrospective comparative study of prostate cancer patient inquiries, comparing responses from human clinical care teams with those generated by a GPT-4-based in-basket bot. Through three rounds of co-evaluations with clinical professionals and an LLM-as-graders study with four LLMs, the RtE method shows that starting with small, iterative evaluations helps human graders adjust metrics to suit their daily practices better. Additionally, in the LLM-as-graders study, LLMs exhibit similar behavior, preferring the in-basket bot's responses over the clinical care team. Our methodology and findings demonstrate that the RtE method can enhance the transparency and robustness of evaluation metrics for LLM-generated content, with the potential to generalize to evaluations in other clinical practices.
Development of a Core Outcome Domain Set for Facial Aging
Dirr, McKenzie A. , Ahmed, Areeba, Schlessinger, Daniel I., Lazaro-Camp, Vanessa, Smith, SJ, Gullapalli, Thanvi, Dragovic, Doroteja, Chang, Joycie, Zhang, Elizabeth, Alam, Murad, Group, Facial Aging Core Outcome Domain Set Study, Anvery, Noor , Kang, Bianca Y. , Wong, Clarissa, Iyengar, Sanjana, Yanes, Arianna F. , Cotseones, Jill, Ashchyan, Hovik J. , Patel, P. M., Sheikh, Umar A., Franklin, Matthew , Hanna, Courtney, Chiren, Sarah G., Schmitt, J, Furlan, Karina C., Alexiades, Macrene, Alhusayen, Raed, Alster, Tina S. , Beer, Kenneth, Bertucci, Vince , Bloom, Jason D. , Briceño, César A., Bucay, Vivian, Butterwick, Kimberly J., Hugues, Cartier, Casabona, Gabriela, Connolly, Karen , Cox, Sue Ellen , Darmanescu, Monica, Boulle, Koenraad De , Desai, Shraddha, Donofrio, Lisa, Dover, Jeffrey S., Draelos, Zoe, Eisen, Daniel B. , El-Domyati, Moetaz, El-Garem, Yehia, Fischer, John, Fitzgerald, Rebecca, GALADARI, Hassan, Gladstone, Hayes B., Goldman, Mitchel P., Goodman, Greg J., Hanke, C. William , Humphrey, Shannon, Ibrahim, Sherrif F., Jagdeo, Jared, Karen, Julie, Kauvar, Arielle, Ag, Kibbi, KIM, JENNY, Lacerda, D T D, Lask, G, Lopez, Grace M., Lupo, Mary P. , Mariwalla, Kavita , Matarasso, Seth, Mekokishvili, L, Narins, Rhoda S., Ogilvie, P, Orringer, Jeffrey S. , Osaki, Tammy H. , Ozog, David, Pacheco, Theresa, Polder, Kristel, Rossi, Anthony M, Sadick, Neil, Saedi, Nazanin, Schlessinger, Joel, Sharad, Jaishree , Shenoy, SuchitraM, Sinclair, Rd, Solish, Nowell, Piansay‐Soriano, Miriam Emily , Sulyman, Omotara , Szeimies, Rolf‐Markus , Tanzi, Elizabeth L., Taub, Amy Forman , Taylor, Mark B., Thomas, J. Regan, Torezan, Luis, Tosti, Antonella, Touma, Dany, Almeida, Ada Regina Trindade de , Vedamurthy, Maya , Viana, Giovanni, Waldman, Abigail, Weinkle, Susan, Weiss, Robert, Poon, Emily, Cartee, Todd V. , Sobanko, Joseph F. , Eisen, Daniel B. , Ahmed, Areeba , Schlessinger, Daniel Isaac , Lazaro-Camp, Vanessa J, Christensen, Rachel E. , Ibrahim, Sarah A. , Cotseones, J.K., Umar, Sheikh Ahmad , Furlan, Karina Colossi , Alexiades, Macrene , Alhusayen, Raed , Beer, Kenneth Robert, Briceño, César Augusto , Bucay, Vivian , Casabona, Gabriela , Cotofana, Sebastian , Desai, Shraddha , Dover, Jeffrey S. , Draelos, Zoe Diana , Eisen, Daniel B., El-Domyati, Moetaz M. , El-Garem, Yehia, Fitzgerald, Rebecca, Friedmann, Daniel P. , Galadari, Hassan , Gladstone, Hayes B., Goldman, Mitchel P. , Goodman, Greg , Green, Jeremy B. , Halachmi, Shlomit , Humphrey, Shannon , Jagdeo, Jared R. , Jiang, Shang I. Brian , Kauvar, Arielle N.B. , Kibbi, Abdul‐Ghani , Kim, John V. S., LASK, GARY P., Matarasso, Seth L., Narins, Rhoda S., Ogilvie, Patricia , Osaki, Tammy H. , Pacheco, Theresa , Polder, Kristel D., Saedi, Nazanin, Shenoy, Manjunath , Sinclair, Rod, Solish, Nowell , Torezan, Luís , Tosti, Antonellá , Waldman, Abigail , Weiss, Robert, Maher, Ian A. , Kirkham, Jamie J

Mayo Clinic

JAMA Dermatology | June 17, 2026 | Volume: 162 | Issue: 8 | Pages: 829

10.1001/jamadermatol.2026.1697 | PMID 42307924 Get It

Importance Currently, there are no standardized outcome domains or measures in clinical trials for facial aging. Heterogeneity in outcome domains and measurement instruments across clinical trials creates difficulty in directly comparing interventions, determining superior therapies, and developing high-quality meta-analyses. Objective To develop a core outcome set (COS) of essential domains to be reported in clinical trials evaluating the efficacy of interventions for facial aging. Evidence Review PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials, and CINAHL were searched from September 2005 to September 2015. An updated search of the same databases was performed from September 2015 to February 2026. Studies were included if (1) they were randomized clinical trial or controlled clinical trial in design, (2) they assessed the efficacy or safety of an intervention for facial aging, (3) they were published in English, and (4) they involved human participants. Complementary sources, including patient interviews, were used to capture further relevant outcomes. Two rounds of Delphi surveys, followed by consensus meetings, were used to identify outcome domains considered most important by both patient and physician stakeholders. Findings The final COS consists of 6 outcome domains: (1) overall convenience of treatment; (2) time to return to normal work and social activity; (3) overall assessment of focused area of treatment (at the point in time when treatment is expected to provide peak benefit); (4) duration of treatment effect; (5) severity of persistent local or systemic adverse events, including pigmentary change, skin texture change, delayed healing, scarring, and serious adverse events; and (6) patient satisfaction with treatment. Conclusions and Relevance The 6 outcome domains identified through a Delphi consensus are recommended for reporting in future facial aging trials to ensure that outcomes that matter most to patients and clinicians are measured and that results are comparable across interventions.
AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich Ataxia
Crystal, R G, Weinsaft, Jonathan W. , Kaminsky, S B, Caragiulo, Anthony, Savage, Niamh, Patel, A, Gavrilova, Ralitza H. , Perlman, Susan , Galbraith, Madeline, Kahlon, Udhay, Krishnan, UM, Sanders, Abraham, Vo, Mary, Sarva, Harini, Yoo, Andrea, Sondhi, Dolan , De, Bishnu P., Mezey, Jason G. , Khan, Aashir, Selvan, Nithya, Bhalla, N P, Adler, Eric, Zesiewicz, Theresa, Caragiulo, Anthony , Patel, Aarti , Kaner, Robert J. , Yoo, Andrea S. , Aubert, Grégory , Selvan, Nithya, Bhalla, Naman Kumar

Mayo Clinic

JAMA Cardiology | June 17, 2026 | Volume: 11 | Issue: 8 | Pages: 709

10.1001/jamacardio.2026.1699 | PMID 42307907 Get It

Importance Friedreich ataxia (FA), a fatal, autosomal recessive disorder caused by pathogenic variants in the frataxin ( FXN ) gene, is characterized by progressive neurologic and cardiac disease, with cardiac disease being the major cause of death. Preclinical studies have demonstrated that systemic administration of AAVrh.10hFXN, an rh.10 serotype cardiotropic adenoassociated virus (AAV) vector expressing the normal human FXN coding sequence, reverses the cardiomyopathy in FXN-deficient mice. Objective To assess the safety and preliminary efficacy of administration of AAVrh.10hFXN to adults with FA cardiomyopathy. Design, Setting, and Participants This nonrandomized clinical trial evaluates the pooled data of 2 independent, open-label, dose-escalation trials that used the same gene therapy vector and similar clinical protocols among patients with FA cardiomyopathy at academic medical centers. Data were collected from February 22, 2022, to October 4, 2025, for trial 1 and from February 14, 2023, to September 10, 2025, for trial 2 and analyzed together from November 5, 2025, to March 12, 2026. Intervention AAVrh.10hFXN, administered intravenously in 3 dose cohorts (1.8 × 10 11 , 5.6 × 10 11 , and 1.2 × 10 12 vector genomes per kilogram of body weight). Main Outcomes and Measures In addition to safety as the primary outcome, multiple parameters of exploratory end points were assessed, including cardiac biopsy levels of FXN protein, cardiac magnetic resonance imaging–derived left ventricular mass index (LVMI), and serum high-sensitivity (hs) troponin I. Results Seventeen patients with FA cardiomyopathy (mean [SD] age, 25 [6] years; 11 [65%] female) were followed up for a mean (SD) of 20 (8) months. There were 4 serious adverse events, 3 possibly related to prednisone immunosuppression and 1 possibly vector-related myocarditis 12 months after therapy, all of which resolved. Other adverse events were transient, nonserious, or not treatment related. In all 8 patients with cardiac biopsy 3 months after therapy, there were higher levels of cardiac FXN (dose cohort 1, 20%; cohort 2, 81%; cohort 3, 123%). After therapy, LVMI was lower by at least 10% in 9 patients and stabilized in 8 patients. Excluding the patient with myocarditis, posttherapy values of serum hs troponin I were lower by at least 10% in 15 patients and higher by at least 10% in 2 patients. Conclusions and Relevance Findings of this nonrandomized clinical trial suggest that intravenous administration of AAVrh.10hFXN was well tolerated and may be a potential treatment for FA cardiomyopathy, as evidenced by preliminary improvement in exploratory efficacy end points. Trial Registration ClinicalTrials.gov Identifiers: NCT05302271 and NCT05445323
Prior exposure to advanced therapy and timing of discontinuation and risk of serious infections in patients with inflammatory bowel disease initiating a new advanced therapy
Solitano, Virginia , Ahuja, D, Qi, Yuchen , Patel, S., Hupé, M, Silverman, Anna L. , Xu, Ronghui, Goodwin, Shane W. , Olén, Ola, Ananthakrishnan, Ashwin N, Jairath, V, Singh, Siddharth, Solitano, Virginia , Ahuja, Dhruv , Hupé, Marianne , Jairath, V , Vuyyuru, Sudheer K. , Xu, Ronghui, Olén, Ola , Ananthakrishnan, Ashwin N. , Jairath, Vipul , Singh, S

Mayo Clinic

Journal of Crohn's and Colitis | June 16, 2026 | Volume: 20 | Issue: 6 | Pages: No page available

10.1093/ecco-jcc/jjag095 | PMID 42377915 Get It

Abstract Introduction Despite regulatory mandates for advanced therapy (AT) washout periods of up to 5 drug half-lives before enrolling patients in inflammatory bowel disease (IBD) trials, the evidence base for these requirements is largely empirical, and whether shorter intervals independently increase the risk of serious infections in real-world practice remains unknown. Methods Using the OptumLabs Data Warehouse, we identified adult patients with IBD who initiated a new AT (tumor necrosis factor antagonists, vedolizumab, interleukin (IL)-12/23 or IL-23 antagonists, or Janus kinase inhibitors) between 2018 and 2023 using a class-specific new-user design. We examined whether exposure to AT within the preceding 12 months (vs no exposure to AT within that window) and timing of discontinuation (≤1 month, 1-<3 months, or 3-12 months) were associated with risk of serious infections using multivariable Cox proportional hazards regression. Results Among 21 564 AT initiators (47 ± 18 years; 52% female; 57% Crohn’s disease), 7490 (34.7%) had AT exposure within the preceding 12 months. Over a mean follow-up of 1.6 ± 0.9 y, 1955 (9.1%) experienced a serious infection. Prior AT exposure was associated with higher infection risk (hazard ratio [HR]: 1.19, 95% confidence interval [CI]: 1.07-1.33), consistent in inverse probability of treatment-weighted analyses (HR, 1.20 [1.06-1.37]). Among patients with prior exposure, timing of discontinuation was not associated with infection risk (HR, 1.17 [0.95-1.43] for ≤1 month vs 3-12 months; HR, 1.01 [0.83-1.22] for 1-<3 months), with no dose–response relationship on continuous modeling. Discussion AT exposure within the preceding 12 months is associated with modestly higher risk of serious infection after initiating a new AT in IBD, but timing of discontinuation does not independently influence this risk.
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026
Patel, Anand , Patel, Anand , Pollyea, Daniel Aaron , Altman, Jessica K. , Assi, Rita, Bachiashvili, Kimo, Bhatt, Vijaya Raj , Fathi, Amir T. , Fedorov, Kateryna, Foran, James M. , Gojo, Ivana , Goldberg, Aaron, Hall, Aric C. , Jonas, Brian A., Levine, Matthew R., Mangan, James, Mannis, Gabriel N. , Marcucci, Guido , Mims, Alice S , Moriarty, Kelsey, Ali, Moaath Mustafa, Neff, Jadee , Nejati, Reza , Olin, Rebecca L. , Patel, Anand, Percival, Mary‐Elizabeth M. , Perl, Alexander E. , Pettit, Kristen, Rao, Dinesh S. , Ravandi‐Kashani, Farhad, Schwabkey, Zaker, Shallis, Rory, Stahl, Maximilian, Stone, Richard M. , Thota, Swapna, Uy, Geoffrey L., Walker, Alison, Wang, Eunice, Awotiwon, Ajibola, Roth, Sydney L., Stehman, Katie

Mayo Clinic

Journal of the National Comprehensive Cancer Network | June 15, 2026 | Volume: 24 | Issue: 6 | Pages: 222-229

10.6004/jnccn.2026.0028 | PMID 42297017 Get It

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues. It is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths from leukemias in the United States. 1 The NCCN Guidelines Panel for AML convenes annually to update recommendations for the diagnosis and treatment of AML in adults. These recommendations are based on a review of recently published clinical trials that have led to significant improvements in treatment or have yielded new information regarding biologic factors that may have prognostic importance. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding the monitoring and management of measurable (minimal) residual disease.
Myelodysplastic Syndromes in VEXAS
Patel, Bhavisha A. , Calvo, Katherine R. , Reichard, Kaaren K. , Patnaik, Mrinal M.

Mayo Clinic

Blood Advances | June 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2025018827 | PMID 42284697 Get It

VEXAS syndrome is a clonal hemato-inflammatory disorder impacting older, predominantly male patients, characterized by systemic inflammation and progressive bone marrow failure. It is caused by somatic mutations in UBA1, an X-linked gene, essential for initiating cellular ubiquitination. Loss-of-function mutations, most commonly M41 missense variants, lead to decreased expression of the cytoplasmic isoform, UBA1b, resulting in accumulation of misfolded proteins and activation of the endoplasmic reticulum stress pathway. Patients classically present with systemic and often refractory inflammation, requiring chronic glucocorticoid treatment and targeted immunosuppressive therapies. A central hallmark of this syndrome is progressive bone marrow failure and associated cytopenia, with a diagnosis of myelodysplastic syndromes (MDS) being reported in approximately 30-50% of patients while only 1% of unselected MDS patients have UBA1 mutations. This review examines current literature on distinct MDS features reported in VEXAS syndrome. We first summarize the defects and alterations in the hematopoietic system from UBA1 mutations, including associated peripheral blood and bone marrow findings. Next, we describe the histological and molecular characteristics of patients with VEXAS syndrome, with and without MDS, and review potential treatment strategies, including responses to hypomethylating agents. Finally, we highlight that VEXAS-associated MDS is a challenging diagnosis but one with unique clinical, laboratory, and morphological features, including prognostic implications.
Real-world treatment and outcomes in hairy cell leukemia: a multicenter retrospective cohort including BRAF inhibitor therapy
Fradin, James J. , Rein, Lisa, Szabo, Aniko, Carlson, Karen-Sue, Badar, Talha, Holden, Troy, Shah, Shiv , Im, Annie, Patel, Anand , Atallah, E., Patel, Anand , Rein, Lisa , Aniko, Szabo, Carlson, Karen , Badar, Talha , Im, Annie , Atallah, Ehab

Mayo Clinic

Leukemia & Lymphoma | June 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-9

10.1080/10428194.2026.2684259 | PMID 42281276 Get It

Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies
Braun, David, Dana, Nicholas, Hernan, Hilary R., Scribano, Christina, Johnson, Christin , Vedder, Lindsey, Euw, Erika von , Zweng, Julie, Wargowski, Ellen, Sunil, Aishwarya , Sharma, D, Routh, Josh, Rexroad, Katherine, McDonnell, Payton , Jergens, Victor, Costa, Catarina, Zuniga, Richard, Patel, Paras M., Martin, Robert C.G., Majeed, Umair, Mukhopadhyay, Debabrata, Lou, Yanyan, Kokabi, Nima, Jakub, James W., Hays, David, Godwin, Andrew K., Giffi, Victoria, Gelbard, Alexander, Friedl, Andreas, Duimstra, Emma Kate, Dronca, Roxana S., Chen, Ruqin, Chalfin, Heather, Broome, Barbara , Babiker, Hani M., Chandra, Tarun, Caenepeel, Sean, Hrycyniak, Laura , Sood, Chetan , Ramos, Hilario, Patel, Premal , Advani, Pooja, Gierman, Hinco J., Taube, Janis, Braun, David , Sahni, Shalini, Scribano, Christina M. , Wargowski, Ellen , Zuniga, Richard, Toia, Giuseppe V. , Martin, Robert C.G. , Majeed, Umair , Mukhopadhyay, Debabrata , Lou, Yanyan , Kokabi, Nima , Jakub, James W. , Godwin, Andrew K. , Gelbard, Alexander , Friedl, Andreas , Dronca, Roxana , Chen, Ruqin, Chalfin, Heather J., Babiker, Hani M. , Caenepeel, Sean , Ramos, Hilario J. , Patel, Premal, Advani, Pooja , Gierman, Hinco J. , Taube, Janis M

Mayo Clinic

No container title available | June 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.05.26354635 Get It

Summary Functional ex vivo assays using live tumor tissues have demonstrated strong predictive accuracy for response to immune checkpoint inhibitors (ICIs) but are not scalable, requiring manual processing of large resections collected at academic centers. Here, an ex vivo live tumor fragment (LTF) platform was developed using standard-of-care biopsies from 228 patients with suspected malignancy collected across prospective, multicenter observational trials and biobanks. Hierarchical clustering of ICI-mediated changes in cytokine production identified two groups: responders and nonresponders. A binary classifier (elive index) using 8 cytokines achieved an AUC of 0.99 for cluster prediction. elive index correctly predicted clinical benefit in 93% (26/28) of patients ( P = 3.2x10 -5 ) and accurately identified 83% (10/12) of objective responders. Critically, elive responders were identified among biomarker-negative patients, highlighting the platform as a scalable approach that complements existing companion diagnostics and expands the population of patients identified to benefit from ICI therapy.
Performance of Successive Generative Pre-trained Transformer (GPT) Models in Medical Cases and Board-style Questions (P9-14.010)
Patel, Anshum , Contractor, Het, Heninger, Hayden, Vallamchetla, Sai Krishna , Li, Pengze, Tao, Cui, Cheung, Joseph, Tao, Cui

Mayo Clinic

Neurology | June 10, 2026 | Volume: 106 | Issue: 11_Supplement_1 | Pages: No page available

10.1212/wnl.0000000000217415 Get It